2. Cell Cycle/DNA Damage
    Cytoskeleton
  3. PAK

PAK

PAK

Related Products

PDF 0.04 MB

PAKs (p21-activated kinases) are a family of six serine/threonine kinases that act as key effectors of RHO family GTPases in mammalian cells. PAKs are subdivided into two groups: group I (PAK1, PAK2, and PAK3) and group II (PAK4, PAK5, and PAK6), based on their domain architecture and regulation. Group I PAKs are activated by GTPases such as Cdc42, Rac, TC10, CHP, and Wrch-1, as well as in a GTPase-independent manner. Group II PAKs are generally not activated by Cdc42/Rac binding. PAK plays important roles in cytoskeletal organization, cellular morphogenesis, and survival, and members of this family have been implicated in many diseases including cancer, infectious diseases, and neurological disorders.

PAKs participate in various signaling networks. PAKs activate the MAPK pathway by phosphorylating Raf1 in addition to NF-κB. PAKs also phosphorylate a number of regulators of the cytoskeleton such as MLCK, LIMK, filamin A, ILK, merlin, and Arpc1b. In addition, PAKs regulate survival and apoptotic pathways through phosphorylation of its effectors such as DLC1 and BimL. On translocation to the nucleus, PAKs directly affect gene transcription. Several transcription factors and transcriptional co-regulators such as FKHR, SHARP, CTBP1 and SNAI1 are substrates to PAK1. PAKs also regulate cell cycle progression through phosphorylation of histone H3, Aurora A and PlK1.

PAK Related Products (69):

Cat. No. Product Name Effect Purity
  • HY-12005
    Fingolimod hydrochloride Activator
    Fingolimod (FTY720) hydrochloride is a sphingosine 1-phosphate (S1P) antagonist with IC50 of 0.033 nM in K562 and NK cells. Fingolimod hydrochloride is also a pak1 activator and immunosuppressant[1][2][3][4].
  • HY-11063
    Fingolimod Activator 99.97%
    Fingolimod (FTY720 free base) is a sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod also is a pak1 activator, a immunosuppressant[1].
  • HY-13007
    PF-3758309 Inhibitor 99.79%
    PF-3758309 (PF-03758309) is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation[1][2][3].
  • HY-15663
    IPA-3 Inhibitor
    IPA-3 is a selective non-ATP competitive PAK1 inhibitor with IC50 of 2.5 μM, and shows no inhibition to group II PAKs (PAKs 4-6).
  • HY-15027
    5-Aminosalicylic Acid Inhibitor
    5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).
  • HY-170380
    XY221 Inhibitor
    XY221 (Compound 16o) selectively inhibits BRD4 BD2, with an IC50 of 5.8 nM. XY221 demonstrates high pan-BD2 selectivity (667-fold over BRD4 BD1) and BRD4 BD2 domain selectivity (9−32-fold over BRD2/3/T BD2). XY221 induce Apoptosis in MV4-11 cells and shows anticancer activity [1].
  • HY-15027S4
    5-Aminosalicylic acid-d7 Inhibitor
    5-Aminosalicylic acid-d7 (5-ASA-d7; Mesalamie-d7; Mesalazie-d7) is deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN)[1].
  • HY-171034
    PQA-18 Inhibitor 99.62%
    PQA-18 is a unique PAK2 inhibitor (IC50: 10 nM). PQA-18 has immunosuppressing effects. PQA-18 suppresses IL2, IL4, IL6, and TNFα. PQA-18 inhibits the population of a subset of regulatory T cells and the immunoglobulin (Ig) production against T cell-dependent antigens as well as alleviates dermatitis in mice[1].
  • HY-19635A
    G-5555 hydrochloride Inhibitor 98.26%
    G-5555 hydrochloride is a potent and selective p21-activated kinase 1 (PAK1) inhibitor with a Ki of 3.7 nM.
  • HY-RS09992
    Pak3 Rat Pre-designed siRNA Set A Inhibitor

    Pak3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Pak3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

  • HY-11063S1
    Fingolimod-d4 hydrochloride Activator
    Fingolimod-d4 (hydrochloride) is the deuterium labeled Fingolimod hydrochloride. Fingolimod hydrochloride (FTY720) is a sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod hydrochloride (FTY720) also is a pak1 activator, a immunosuppressant[1].
  • HY-146681
    PAK1-IN-1 Inhibitor
    PAK1-IN-1 is a potent and selective PAK1 inhibitor with an IC50 of 9.8 nM. PAK1-IN-1 inhibits the migration and invasion of PAK1-related tumour cells in a dose-dependent manner[1].
  • HY-RS09997
    Pak5 Mouse Pre-designed siRNA Set A Inhibitor

    Pak5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pak5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

  • HY-124764
    KY-04031 Inhibitor
    KY-04031 is a potent PAK4 inhibitor with IC50 of 0.79 μM. KY-04031 binds to the ATP-binding pocket of PAK4. KY-04031 blocks tumor cell growth and invasion[1].
  • HY-RS09989
    PAK2 Rat Pre-designed siRNA Set A Inhibitor

    PAK2 Rat Pre-designed siRNA Set A contains three designed siRNAs for PAK2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

  • HY-164488
    KT D606 Inhibitor
    KT D606 is an inhibitor of the PAK kinase family, with an IC50 value of 4 μM. KT D606 selectively blocks the proliferation of cancer cells transformed by oncogenic RAS mutants and can be used for research on RAS/PAK1-induced cancers[1].
  • HY-120940A
    AZ13705339 hemihydrate Inhibitor 99.77%
    AZ13705339 hemihydrate is a highly potent and selective PAK1 inhibitor with IC50s of 0.33 nM and 59 nM for PAK1 and pPAK1, respectively. AZ13705339 hemihydrate has binding affinities to PAK1 and PAK2, with Kds of 0.28 nM and 0.32 nM, respectively. AZ13705339 hemihydrate can be used in the research of cancers[1].
  • HY-155179
    ZMF-23 Inhibitor
    ZMF-23 is a PAK1/HDAC6 dual inhibitor. ZMF-23 inhibits PAK1 and HDAC6 regulated aerobic glycolysis and migration. ZMF-23 induces TNF-α-regulated necroptosis, and further enhances apoptosis. ZMF-23 inhibits the Warburg effect and cell migration. ZMF-23 can be used for research of triple-negative breast cancer (TNBC)[1].
  • HY-11063S
    Fingolimod-d4 Activator 98.97%
    Fingolimod-d4 is the deuterium labeled Fingolimod. Fingolimod (FTY720 free base) is a sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod also is a pak1 activator, a immunosuppressant[1].
  • HY-15542B
    FRAX486 Inhibitor 98.01%
    FRAX486 is a p21-activated kinase (PAK) inhibitor with IC50s of 14, 33 and 39 nM for PAK1, PAK2 and PAK3, respectively.